NRX Pharmaceuticals (NRXP) - Imminent Catalyst and other statuses! This company is on the move and gaining traction. Price targets are multiples of the current share price.
**NRXP - Severe Depression, PTSD**
***FINALLY, IT's TIME!*** **They are at the finish line for one of three drugs!**
Been following this company for well over a year. Posted about them a year ago. Major progress since then.
* **IMMINENT FDA decision:**
* **GDUFA (generic drug) date** of 7/29/2026 has passed with no word yet from the FDA on a decision for the **ANDA** submission for **KETAFREE**, which is a **preservative‑free IV ketamine formulation** for the following indications: sedation/anesthesia and analgesia (pain management).
* Does NOT contain the known toxic preservative, benzethonium chloride (BZT), which is used in current ketamine formulations found in multi-dose vials.
* **HOWEVER, on 7/31 there was a CEO update on NRXP's website**, which is HIGHLY encouraging for a potential approval: [https://www.nrxpharma.com/management-answers-to-shareholder-questions/](https://www.nrxpharma.com/management-answers-to-shareholder-questions/)
* "**July 31, 2026**
* "Investors have inquired about the status of NRx’s ANDA application for **preservative-free ketamine**. The company has been advised that there are no Major Deficiencies related to the drug product, API, formulation, labeling, and related matters. The Company has been engaged with FDA in review of the packaging, which includes an innovative luer lock vial already used in allowing for needle-free withdrawal of the medication, unlike traditional glass vials. The FDA has advised the company to anticipate a determination on the packaging today."
* **Other relevant facts:**
* Raised $7M in post-Q1 stock sales
* Raised $22.3M at $3.50/share, in an underwritten public offering (June 4, 2026)
* Manufacturing of KETAFREE is in the U.S.
* Per the CEO: can produce 1M units per week and will have 1M units warehoused at launch
* Filed a **Citizen Petition,** asking the FDA to require the elimination of benzethonium chloride (BZT) — a preservative still present in most multi‑dose ketamine vials but **not recognized as safe by FDA**
* **NRX-100 (Preservative-free** **IV Ketamine formulation)**
* **For the following indications:**
* Suicidal ideation in major depressive disorder
* Suicidal ideation in bipolar depression
* Treatment‑resistant depression with suicidality (broader indication proposed)
* **NDA (Fast Track) submission in final stages.**
* Target Date: June 30, 2026.
* Date has passed, so presuming submission may be imminent
* **NRX-101**
* **Fixed‑dose combination** **of:**
* D‑cycloserine (DCS) — an NMDA receptor modulator
* Lurasidone — a 5‑HT2A antagonist used in bipolar depressio**n**
* **Indications:**
* **Together, they are the first drug in FDA trials specifically for suicidal bipolar depression**
* **PTSD**
* **Breakthrough Therapy Designation (BTD)**
* **Expanded Access Protocol** **(EAP)** — FDA‑authorized compassionate use
* **Phase 2/3 pivotal trials underway**
* Has begun the **SPARC‑TMS pivotal trial**, evaluating NRX‑101 + accelerated, neuro-navigated robotic TMS
* Conducted in NRXP's HOPE clinics and military treatment facilities
* **HOPE Therapeutics**
* NRXP has acquired numerous neuropsychiatric clinics in Florida over the past 18 months
* Partnered with Neurocare Group, gaining access to 400 TMS Clinics nationwide
* Creates a nationwide “integrated neuroplastic therapy” platform
* **Major Hire Announcement - April 15, 2026**
* NRXP appoints Former **Senior Defense Department Executive** Dr. Dennis K. McBride, a career military medical scientist, to lead **NRx Defense Systems**
* NRx is positioning **NRX‑101 + robotic‑enabled TMS** as a Defense Department–relevant technology for:
* Military readiness
* First responder resilience
* Rapid treatment of depression, suicidality, and PTSD‑related conditions
